Nomination of new Director for Rochester Site
Unither Pharmaceuticals welcomes Pablo Martinez as the new Rochester Site Director
Rochester, New York (United States), November 3, 2026 – Unither Pharmaceuticals (“Unither” or “the Group”), an international pharmaceutical contract development and manufacturing organization (“CDMO”), is pleased to announce the appointment of Pablo Martinez as Site Director of its Rochester facility. He has overall responsibility for the leadership and performance of the site.
The appointment comes as Unither continues to develop its presence in the United States. Following significant investment in the modernization and expansion of its Rochester facility, the site is strengthening its capacity for preservative-free sterile products to support growing customer needs in the US market. The development of the Rochester plant is part of Unither’s strategy to bring manufacturing & development capabilities closer to customers and their markets.
Henrik Kruepper, CEO of Unither Pharmaceuticals, said: “Pablo’s appointment comes at an important stage in the development of our Rochester site. His extensive experience in pharmaceutical manufacturing and operations will support our ambitions for the site, with a continued focus on safety, quality and compliance, our people, our customers, and operational performance.”
Pablo Martinez, Site Director, Rochester, added: “I am pleased to join Unither and the Rochester team at an important stage in the site’s development. I look forward to working with our teams to strengthen our operations, deliver on our commitments to customers, and support the continued development of Rochester.”
Biography of Pablo Martinez
Pablo Martinez brings more than 30 years of experience in pharmaceutical manufacturing and operations. Prior to joining Unither Pharmaceuticals, he served as Vice President and Site General Manager at Teva Pharmaceuticals and held senior leadership positions at Sanofi Genzyme, GSK, Novartis, and Par Pharmaceutical. He holds an MBA in Operations Management from NYU Stern School of Business and a B.S. in Chemical Engineering from the University of Delaware.

About Unither Pharmaceuticals
Unither Pharmaceuticals is an international pharmaceutical contract manufacturer specializing in the development and production of liquid formulations in unit-dose and multi-dose formats, including ophthalmic products, saline solutions, and asthma medications using Blow-Fill-Seal (BFS) technology.
The Group employs 2,300 people and operates eight production sites in France, the United States, Brazil, and China, as well as an R&D center in France. In 2025, Unither Pharmaceuticals generated revenue of €512 million.
For more information, please visit: www.unither-pharma.com